Treatment with mesalamine resulted in a modest but significant reduction in IL‐6 and STAT3 content by 12.71% (F = 505.4, p = 0.006) and 53.57% (F = 153.3, p = 0.004), respectively, relative to the colitis group. This evidence concerns the gene IL6 and colitis.